Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors

Clinical trial NCT05003622 · COMPLETED

Trial details

NCT number: NCT05003622
Sponsor: Pierre Fabre Medicament
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

BRAF V600E Unresectable or Metastatic Melanoma BRAF V600E Metastatic NSCLC Melanoma

Start date: 2021-09-27
Primary completion: 2022-05-06
Enrollment: 3

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.